Radar · Life Sciences Tech in California
Best Life Sciences Tech Companies in California, United States
The 632 best Life Sciences Tech companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Xaira.
By Rohit KhannaTrends & Stories
632companies tracked
$15.6Bdisclosed funding
9unicorns
331have raised
FLIAR INTELLIGENCE · LIFE SCIENCES TECH × CALIFORNIA
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
89%cloud-native stacks
2025funding peak (by rounds)
8unicorns
2018median founding year
921kcombined LinkedIn audience
61%of audience held by top 3
6companies hiring publicly (12 mo)
Ranked: Best Life Sciences Tech companies in California
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Xaira 🦄 AI-enabled platform for drug discovery and development 55Funding top 22%Talent top 23%Moat top 26%Growth top 45% All 7 signals ▾Fundingtop 22% Talenttop 23% Moattop 26% Growthtop 45% Markettop 50% Techbottom 41% Globalbottom 36% Funding: Raised $1.0B across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 5 named leaders on record · 5 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $1.0B | 25 mo ago | Series D | — | Robert Nelsen Co-Founder & Director | — | 1 job opening · 1 award |
| 2 | Eikon 🦄 Protein tracking and measuring tool for drug discovery 60Funding top 14%News top 28%Moat top 28%Market top 38% All 10 signals ▾Fundingtop 14% Newstop 28% Moattop 28% Markettop 38% Growthtop 40% Techtop 43% Talenttop 44% Globalbottom 42% Patentsbottom 38% Innovationbottom 36% Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $668M | 16 mo ago | Public | 331 | Robert Tjian Co-Founder | 9 patents Automated vehicle intrusion barriers for rapid security deployment | — |
| 3 | Human Longevity Provider of precision medicine, preventative health assessments, and longevity care | $409M | 21 mo ago | Series B | 85 | J Venter Co-Founder & CEO | 71 patents AI-driven multi‑omic analytics for disease risk assessment, diagnosis, and genomic trait prediction | 1 launch · 1 partnership |
| 4 | Innovaccer 🦄 Developer of healthcare data platforms and artificial intelligence agent software 93Funding top 23%Tech top 25%AI top 25%Moat top 25% All 13 signals ▾Fundingtop 23% Techtop 25% AItop 25% Moattop 25% Markettop 26% Fin. healthtop 28% Talenttop 28% Innovationtop 29% Patentstop 32% Growthtop 33% Producttop 38% Globaltop 42% Newsbottom 24% Funding: Raised $379M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Tech: 43 technologies across 6/8 capability areas · Cloud: Amazon S3, Amazon Ses rank vs industry peers · Fliar Intelligence Index 93/100 | $379M | 17 mo ago | Series F | 1,003 1,003 → 1,712 (+71%) · sector median -2% | Abhinav Shashank Co-Founder & CEO | 30 patents Integrating and analyzing de‑identified healthcare data across clouds for clinical decision support | 1 partnership |
| 5 | Genesis Therapeutics Developer of an AI platform for discovering and designing novel drugs 48Funding top 23%Moat top 28%AI top 30%Tech top 35% All 9 signals ▾Fundingtop 23% Moattop 28% AItop 30% Techtop 35% Talenttop 38% Growthbottom 42% Globalbottom 37% Marketbottom 26% Newsbottom 21% Funding: Raised $280M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 48/100 | $280M | 19 mo ago | Series B | 10 | Ben Sklaroff Co-Founder & CTO | — | — |
| 6 | Evidation Real-world health data insights for better healthcare decisions and research 72Funding top 20%Customers top 27%Tech top 31%Moat top 31% All 10 signals ▾Fundingtop 20% Customerstop 27% Techtop 31% Moattop 31% Producttop 36% Talenttop 38% Growthtop 41% Markettop 43% Globalbottom 37% Newsbottom 22% Funding: Raised $259M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) Customers: App rating 4.2★ (20,400 reviews) · Review volume +3% in 6 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $259M | 15 mo ago | Series E | 196 196 → 101 (-48%) · sector median -2% | Christine Lemke Co-founder | — | — |
| 7 | Chai Discovery 🦄 Developer of artificial intelligence models for de novo molecular design 72Funding top 14%Talent top 28%AI top 30%Moat top 32% All 7 signals ▾Fundingtop 14% Talenttop 28% AItop 30% Moattop 32% Markettop 48% Globalbottom 48% Techbottom 42% Funding: Raised $230M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $230M | 6 mo ago | Series B | — | Joshua Meier Co-Founder | — | 1 partnership |
| 8 | Neuron23 AI-based drug discovery model for researchers 80Growth top 13%Funding top 18%Patents top 21%Moat top 21% All 10 signals ▾Growthtop 13% Fundingtop 18% Patentstop 21% Moattop 21% Innovationtop 23% AItop 45% Talentbottom 49% Globalbottom 40% Marketbottom 38% Newsbottom 18% Growth: Headcount 12 → 29 (+142%) across vintages · Fresh capital in last 24 mo Funding: Raised $214M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $214M | 11 mo ago | Series D | 29 29 → 28 (-3%) · sector median -2% | Adam Knight Founder & CBO | 49 patents LRRK2 kinase inhibitor therapeutics and biomarkers for Parkinson's disease treatment | 1 partnership |
| 9 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | Series C | 50 | Fred Manby Co-Founder & CTO | — | — |
| 10 | Terray Provider of AI-based drug candidate identification solutions for drug development | $200M | 20 mo ago | Series B | 50 | — | — | 1 launch · 1 partnership · 1 award |
| 11 | Atomwise Developer of artificial intelligence platform for small molecule drug discovery | $174M | 27 mo ago | Series B | 65 | — | 70 patents AI-driven discovery of small‑molecule inhibitors and virtual chemical library screening | — |
| 12 | BrightInsight Provider of digital health solutions for clinical trials 57Funding top 18%Moat top 31%Growth top 35%Market top 50% All 8 signals ▾Fundingtop 18% Moattop 31% Growthtop 35% Markettop 50% Techbottom 49% Talentbottom 49% Newsbottom 43% Globalbottom 37% Funding: Raised $166M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 57/100 | $166M | 4 mo ago | Series C | 165 165 → 145 (-12%) · sector median -2% | Frederik Smits Co-founder & Managing Director | — | — |
| 13 | Noetik Developer of AI-driven platform for cancer immunotherapy discovery and development | $62M | 22 mo ago | Series A | — | Jacob Rinaldi Co-Founder & CSO | 2 patents Digital pathology image analysis for precision tissue microarray construction | 2 internships |
| 14 | NewLimit 🦄 Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension 62Funding top 22%Talent top 28%Growth top 35%AI top 45% All 9 signals ▾Fundingtop 22% Talenttop 28% Growthtop 35% AItop 45% Techtop 46% Moattop 47% Marketbottom 36% Globalbottom 36% Newsbottom 18% Funding: Raised $60.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 62/100 | $60M | 7 mo ago | Series B | 8 | Jacob Kimmel Co-Founder | — | 4 job openings |
| 15 | Aureka Biotechnologies Biotech company digitizing therapeutic discovery to manage human health 55Funding top 20%AI top 35%Talent top 38%Market bottom 37% All 5 signals ▾Fundingtop 20% AItop 35% Talenttop 38% Marketbottom 37% Globalbottom 36% Funding: Raised $58.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) AI: Product described with: ai-based, artificial intelligence rank vs industry peers · Fliar Intelligence Index 55/100 | $58M | 1 mo ago | Series A | — | Weian Zhao Co-Founder & CEO | — | — |
| 16 | Cartography Biosciences Provider of a platform to discover immunotherapeutics 24Funding top 23%Moat top 31%News top 39%Talent bottom 49% All 6 signals ▾Fundingtop 23% Moattop 31% Newstop 39% Talentbottom 49% Globalbottom 37% Marketbottom 27% Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $57M | 1 mo ago | Series B | 10 | Howard Chang Co-Founder | — | — |
| 17 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | Series B | 25 25 → 31 (+24%) · sector median -2% | Irene Yuan Co-Founder & Executive Vice President | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 18 | Pictor Labs AI-based solutions for pathological image analysis | $49M | 17 mo ago | Series B | 29 | Yair Rivenson Co-Founder & CEO | 6 patents AI-powered digital pathology: virtual staining, immunostain analysis, and analyte detection. | — |
| 19 | Profluent Bio Provider of an artificial intelligence-based protein design platform 50Funding top 23%AI top 30%Talent top 33%Moat top 39% All 8 signals ▾Fundingtop 23% AItop 30% Talenttop 33% Moattop 39% Growthtop 45% Techbottom 45% Globalbottom 37% Marketbottom 28% Funding: Raised $44.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 6 mo ago | Series B | 10 | Alexander Meeske Co-Founder | — | 1 partnership |
| 20 | Glyphic Biotechnologies Developer of a platform for next-generation protein sequencing 50Patents top 25%Moat top 25%Innovation top 28%Funding top 28% All 8 signals ▾Patentstop 25% Moattop 25% Innovationtop 28% Fundingtop 28% Talentbottom 49% Techbottom 46% Globalbottom 40% Marketbottom 37% Patents: 35 patents matched (strict assignee match) · 35 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 35 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $39M | 15 mo ago | Series A | 40 40 → 33 (-18%) · sector median -2% | Joshua Yang Co-Founder & CEO | 35 patents Innovative chemistries for single‑molecule protein/peptide sequencing using guanidinylation and polymerizable coupling. | — |
| 21 | JUMPCODE Genomics Provider of a technology for depleting unwanted nucleic acid | $39M | 15 mo ago | Series B | 27 | — | 57 patents Targeted NGS library preparation, enrichment, and transcriptome analysis technologies | — |
| 22 | Unnatural Products Developer of computational biology techniques platform to engineer peptides for undruggable targets 27Funding top 25%Moat top 48%Global bottom 38%Market bottom 35% All 5 signals ▾Fundingtop 25% Moattop 48% Globalbottom 38% Marketbottom 35% Newsbottom 33% Funding: Raised $38.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Moat: Editorial + unicorn rating 5/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 27/100 | $38M | 3 mo ago | Series B | 22 | — | — | — |
| 23 | Quartzy Provider of web-based platform for labs management 67Funding top 24%Growth top 26%Tech top 37%Innovation top 38% All 10 signals ▾Fundingtop 24% Growthtop 26% Techtop 37% Innovationtop 38% Moattop 39% Producttop 42% Marketbottom 49% Talentbottom 49% Newsbottom 47% Globalbottom 37% Funding: Raised $33.9M across 6 rounds · 6 rounds over 14 yrs (0.4/yr) Growth: Headcount 54 → 97 (+80%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $34M | 2 mo ago | Series C | 97 97 → 92 (-5%) · sector median -2% | Adam Regelman Co-Founder & CPO | — | 1 job opening · 1 launch · 2 partnerships |
| 24 | Triomics Provider of clinical research and clinical trial tracking software 60AI top 20%Funding top 26%Talent top 38%Moat top 39% All 8 signals ▾AItop 20% Fundingtop 26% Talenttop 38% Moattop 39% Techtop 40% Growthtop 47% Globalbottom 43% Marketbottom 35% AI: Classified as an AI company Funding: Raised $28.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $29M | 0 mo ago | Series B | 29 | Hrituraj Singh Co-Founder & CTO | — | — |
| 25 | Uncountable Data Developer of a unified platform for research and development data management 62Talent top 22%Funding top 27%Growth top 35%Tech top 43% All 8 signals ▾Talenttop 22% Fundingtop 27% Growthtop 35% Techtop 43% Moattop 48% Productbottom 48% Marketbottom 43% Globalbottom 37% Talent: Analyst team rating 5/5 · 3 named leaders on record Funding: Raised $27.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $27M | 12 mo ago | Series A | 50 | Noel Hollingsworth Co-Founder | — | — |
| 26 | Condor Software-based financial management platform for clinical industries 29Funding top 27%News top 29%Talent top 38%Tech top 45% All 9 signals ▾Fundingtop 27% Newstop 29% Talenttop 38% Techtop 45% Moattop 48% Innovationbottom 46% Productbottom 45% Globalbottom 32% Marketbottom 21% Funding: Raised $24.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 3 BI events in 12 mo (of 5 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $24M | 3 mo ago | Series A | 8 | John Sammataro Co-Founder | — | — |
| 27 | ValGenesis Validation software for the life sciences companies | $24M | 10 mo ago | Series B | 431 431 → 677 (+57%) · sector median -2% | — | 15 patents Risk‑based validation and lifecycle management software for pharmaceutical manufacturing processes | — |
| 28 | VeriSIM Life AI enabled biosimulation model for drug development 22Funding top 29%AI top 45%Talent bottom 49%Global bottom 37% All 7 signals ▾Fundingtop 29% AItop 45% Talentbottom 49% Globalbottom 37% Techbottom 28% Marketbottom 23% Newsbottom 22% Funding: Raised $21.4M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 22/100 | $21M | 11 mo ago | Series A | 13 13 → 19 (+46%) · sector median -2% | Jyotika Varshney Co-Founder & CEO | — | 1 award |
| 29 | Model Medicines Developer of AI-based drug discovery platform | $20M | 7 mo ago | Series A | 26 | Daniel Haders II Chief Executive Officer | 18 patents Antiviral therapeutics targeting DNA/RNA viruses, including SARS‑CoV‑2, using pipendoxifene. | — |
| 30 | Sinopia Biosciences Data-driven drug discovery using multi-omics, AI, and disease models 13Funding top 28%AI top 45%Global bottom 29%Tech bottom 26% All 5 signals ▾Fundingtop 28% AItop 45% Globalbottom 29% Techbottom 26% Marketbottom 16% Funding: Raised $19.4M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 13/100 | $19M | 2 mo ago | Funding Raised | 4 | — | — | — |
| 31 | Manifold AI Provider of an AI platform for life sciences research and development | $18M | 5 mo ago | Series B | 79 | Sourav Dey Cpo & Co-Founder | 8 patents Patents concentrated in mechanical & energy engineering | 2 launchs · 1 award |
| 32 | General Proximity Developer of next generation of induced-proximity medicines 22Funding top 31%Talent bottom 49%Global bottom 48%Tech bottom 42% All 5 signals ▾Fundingtop 31% Talentbottom 49% Globalbottom 48% Techbottom 42% Marketbottom 24% Funding: Raised $16.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $16M | 1 mo ago | Seed | 11 | Armand Cognetta III Founder & CEO | — | — |
| 33 | HUMA.AI AI-based business development tool for healthcare | $14M | 14 mo ago | Series A | 28 | Lana Feng Co-Founder & CEO | — | 1 launch |
| 34 | Valinor Developer of machine learning models for clinical drug development acceleration 72Funding top 34%Talent top 38%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 34% Talenttop 38% AItop 45% Globalbottom 48% Funding: Raised $13.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $13M | 6 mo ago | Seed | — | Zhanel Nugmanova COO & Co-Founder | — | — |
| 35 | Peer AI Provider of an artificial intelligence to automate and streamline medical writing processes 80Patents top 18%Innovation top 22%AI top 28%Funding top 30% All 7 signals ▾Patentstop 18% Innovationtop 22% AItop 28% Fundingtop 30% Talenttop 45% Techbottom 49% Globalbottom 42% Patents: 62 patents matched (strict assignee match) · 62 filings since 2022 vs 0 in 2017-21 Innovation: 62 patents (top 17% of patent-holders) · 62 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 80/100 | $12M | 8 mo ago | Series B | — | Christopher Ceppi Co-Founder & COO | 62 patents AR/VR portal systems enabling synchronized multi-user virtual environments and dynamic content placement | 1 job opening |
| 36 | NeuroComp Systems Provider of CNS monitoring and electronic data capture software and hardware for the clinical trial | $11M | 16 mo ago | Funding Raised | — | James P OHalloran Founder | — | — |
| 37 | Ryght Generative AI platform focused on biopharma smart biomedical data | $9M | 6 mo ago | Series A | — | Simon Arkell Co-Founder & CEO | — | 1 launch · 2 partnerships |
| 38 | Onyx Life Developer of an AI platform for precision medicine research studies | $8M | 4 mo ago | Series A | — | Amit Lakhani Co-Founder & CTO | — | — |
| 39 | Simulations Plus Developer of modeling and simulation software and consulting services provider 62News top 24%Product top 24%Funding top 28%Fin. health top 33% All 11 signals ▾Newstop 24% Producttop 24% Fundingtop 28% Fin. healthtop 33% Growthtop 37% AItop 45% Techtop 48% Moattop 49% Innovationbottom 48% Marketbottom 47% Globalbottom 37% News: 19 BI events in 12 mo (of 179 tracked, 10 types) · +111% YoY Product: 1 product launch event in 12 mo · 6 distinct product lines rank vs industry peers · Fliar Intelligence Index 62/100 | $8M | 11 mo ago | Public | 197 197 → 197 (+0%) · sector median -2% | — | — | 1 job opening · 1 launch · 1 partnership |
| 40 | Blank Bio Developer of RNA foundation models for precision medicine research applications 60Talent top 28%Funding top 35%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 35% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $7.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $7M | 1 mo ago | Seed | — | Jonathan Hsu Co-Founder & CEO | — | — |
| 41 | Century Health AI-powered health tech company accelerating access to breakthrough treatments 45Funding top 35%Talent top 38%AI top 45%Market bottom 37% All 5 signals ▾Fundingtop 35% Talenttop 38% AItop 45% Marketbottom 37% Globalbottom 29% Funding: Raised $7.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $7M | 1 mo ago | Seed | — | Vish Srivastava Co-Founder & CEO | — | — |
| 42 | Mantis Provider of a cloud-based domain-aware data platform for life sciences 57Funding top 37%AI top 45%Global bottom 48%Talent bottom 45% All 4 signals ▾Fundingtop 37% AItop 45% Globalbottom 48% Talentbottom 45% Funding: Raised $6.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 57/100 | $6M | 7 mo ago | Seed | — | Georgia Witchel Founder & CEO | — | — |
| 43 | SynthioLabs Provider of AI agents for life sciences workflow acceleration | $6M | 6 mo ago | Seed | — | Rajashekar Vasantha Co-Founder | — | — |
| 44 | Expert Intelligence AI-powered solutions to enhance laboratory workflows | $5M | 4 mo ago | Seed | — | Lalin Theverapperuma Founder & CEO | — | — |
| 45 | LighthouseAI Provider of software and services for pharmaceutical state licensing and compliance 40Growth top 35%Tech top 39%Funding top 45%Talent bottom 49% All 7 signals ▾Growthtop 35% Techtop 39% Fundingtop 45% Talentbottom 49% Globalbottom 36% Marketbottom 27% Newsbottom 22% Growth: Fresh capital in last 24 mo Tech: 39 technologies across 5/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 40/100 | $5M | 1 mo ago | Series A | 18 | Sumeet Singh Founder & CEO | — | — |
| 46 | PhnyX Lab AI-powered solutions to simplify workflows in pharmaceutical research | $4M | 10 mo ago | Seed | — | Harshit Gupta Co-Founder | — | — |
| 47 | SiftBio Developer of peptide immunotherapies for cancer and autoimmune diseases | $4M | 6 mo ago | Seed | — | Maddie Williams Co-Founder & CTO | — | — |
| 48 | Nexilico Developer of computational tools for microbiome analytics | $3M | 9 mo ago | Funding Raised | 4 | Mohammad Soheilypour CEO | — | — |
| 49 | Graph Provider of an AI platform for patient safety and regulatory compliance | $3M | 8 mo ago | Seed | — | Mohan K Chief Product Officer & Co-Founder | — | — |
| 50 | ElevateU Developer of AI-powered platforms for research recruitment and opioid misuse reduction | $1M | 6 mo ago | Funding Raised | — | Renee Garett Founder & CEO | — | — |
Top 12 Life Sciences Tech companies in California
#1
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Series C · San Diego, California · founded 2019 · 50 employees
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%AI
top 26%Moat
top 31%Talent
top 38%Growth
top 45%Market
bottom 43%Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series C (Apr 2026)
AI: Classified as an AI company · Product described with: ai driven, ai-driven
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
Founders & team
Investors
Ascenta Capital, Abingworth, Nvidia, Illumina Ventures, Shanda, Catalio Capital Management
Tech stack
Apple Icloud MailCloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesHsts
#2
Series C · San Jose, California · founded 2017 · 165 employees$166.1Mraised▾
Series C · San Jose, California · founded 2017 · 165 employees
BrightInsight provides digital health solutions for clinical trials. Their platform enables improving patient engagement and adherence, continuous remote patient monitoring, and dose management algorithms (cloud-based algorithm). It analyzes data from connected medical devices, combination products, apps, and software. The company's Quality Management System is ISO 13485: 2016 certified.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 18%Moat
top 31%Growth
top 35%Market
top 50%Tech
bottom 49%Talent
bottom 49%Funding: Raised $166M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series C (Jan 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 21k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 2 partnerships (incl. Havas Health Network) announced in 12 mo
Funding rounds
- Jan 2026Series C$13M
- Mar 2021Series C$101M
- Jun 2020Series B$40.1M
- Sep 2019Series A$25M
Founders & team
Investors
General Catalyst, Insight Partners, New Leaf Venture Partners, Eclipse, Mayo Clinic, PROOF
Tech stack
6SenseCloudflareCloudflare Bot ManagementCore-JsDocusignFullstory
#3
Series B · Foster City, California · founded 2020 · 10 employees$57Mraised▾
Series B · Foster City, California · founded 2020 · 10 employees
Provider of a platform to discover immunotherapeutics. It provides a platform that combines computational and experimental techniques to profile antigens of cancerous cells and identify targets for immuno-oncology treatments.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 23%Moat
top 31%News
top 39%Talent
bottom 49%Global
bottom 37%Market
bottom 27%Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- May 2026Series B—
- Oct 2025Series B$67M
- Jul 2022Series A$57M
Founders & team
Investors
8VC, Dren Bio, Hexagon, Myeloid Therapeutics, Alloy Therapeutics, Andreessen Horowitz
#4
Series A · Laguna Hills, California · founded 2023$58Mraised▾
Series A · Laguna Hills, California · founded 2023
Biotech company digitizing therapeutic discovery to manage human health. It utilize microfluidics in use of drug discovery and offer solutions for pharmaceutical and biotech research using artificial intelligence. The platform offers immunotherapeutic discovery, developing new therapeutics, drug discovery, single-cell-based functional screening and AI-based drug design and development for generating multi metric data from analyzing multiple candidates.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 20%AI
top 35%Talent
top 38%Market
bottom 37%Global
bottom 36%Funding: Raised $58.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series A (Apr 2026)
AI: Product described with: ai-based, artificial intelligence
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Principal Scientist (Biotherapeutic Discovery)
Funding rounds
- Apr 2026Series A$35M
- Nov 2025Series A$23M
Founders & team
Investors
5Y Capital, Qiming Venture Partners, Matrix Partners China, Boyuan Capital, NRL Capital, HSG
#5
Series B · San Francisco, California · founded 2023$230Mraised▾
Series B · San Francisco, California · founded 2023
Developer of artificial intelligence models for de novo molecular design. The company focuses on engineering better molecules through advanced computational methods. It introduces new model series designed to achieve high hit rates in antibody design. The company provides access to its technology for molecular research and development.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 14%Talent
top 28%AI
top 30%Moat
top 32%Market
top 48%Global
bottom 48%Funding: Raised $230M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series B (Dec 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
AI: Classified as an AI company · Product described with: artificial intelligence
Audience (LinkedIn): 18k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Pfizer) announced in 12 mo
Funding rounds
- Dec 2025Series B$130M
- Aug 2025Series A$70M
- Sep 2024Seed$30M
Founders & team
Investors
Thrive Capital, OpenAI, Menlo Ventures, Anthropic, Yosemite, DST Global
Tech stack
CloudflareFramer SitesGoogle AnalyticsGoogle Font ApiGoogle WorkspaceHsts
#6
Series B · San Francisco, California · founded 2020 · 29 employees$28.9Mraised▾
Series B · San Francisco, California · founded 2020 · 29 employees
Provider of clinical research and clinical trial tracking software. The features of the software include an end-to-end platform for running clinical trials, unifying the workflows of clinical care and clinical research, and eliminating the operational inefficiencies in data collection, patient recruitment, and other laborious tasks involved in clinical research.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
AI
top 20%Funding
top 26%Talent
top 38%Moat
top 39%Tech
top 40%Growth
top 47%AI: Classified as an AI company
Funding: Raised $28.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding rounds
- May 2024Series B$15M
- Dec 2022Series A$13.8M
- 2021Seed$125K
Founders & team
Investors
Y Combinator, Nexus Venture Partners, General Catalyst, Lightspeed, Battery Ventures, Lightspeed Venture Partners
Tech stack
Amazon Web ServicesBootstrapCalendlyCloudflareCloudflare Bot ManagementCore-Js
#7
Series C · Hayward, California · founded 2009 · 97 employees$33.9Mraised▾
Series C · Hayward, California · founded 2009 · 97 employees
Provider of web-based platform for labs management. It is a cloud-based platform that allows laboratories to streamline their communications, manage inventory, and purchase what they need to hit their milestones faster.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 24%Growth
top 26%Tech
top 37%Innovation
top 38%Moat
top 39%Product
top 42%Funding: Raised $33.9M across 6 rounds · 6 rounds over 14 yrs (0.4/yr) · Last round Series C (Apr 2026)
Growth: Headcount 54 → 97 (+80%) across vintages · Fresh capital in last 24 mo
Tech: 43 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare · Devops: Envoy
Audience (LinkedIn): 11k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Territory Manager
Activity (LinkedIn): 1 product launches · 2 partnerships (incl. Slingshot Biosciences) announced in 12 mo
Funding rounds
- Apr 2026Series C$23M
- Dec 2019Series B$5M
- Jan 2016Series B$17M
- Jul 2013Series A$4M
Founders & team
Investors
Eminence Capital, Khosla Ventures, Y Combinator, A.Capital Ventures, Lerer Hippeau, Reinmkr Satsang
Tech stack
Amazon Web ServicesAtlassian StatuspageCalendlyCart FunctionalityCloudflareCloudflare Bot Management
#8
Series B · Santa Cruz, California · founded 2016 · 22 employees$38Mraised▾
Series B · Santa Cruz, California · founded 2016 · 22 employees
Developer of computational biology techniques platform to engineer peptides for undruggable targets. The company has an AI-enhanced chemistry platform that enables a new class of drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 25%Moat
top 48%Global
bottom 38%Market
bottom 35%News
bottom 33%Funding: Raised $38.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 5/10 · 9 curated direct competitors tracked
Global: Investors from 4 countries beyond United States
Audience (LinkedIn): 10k LinkedIn followers
Funding rounds
- Mar 2026Series B$45M
- Jul 2023Series A$32M
- Sep 2019Seed$6M
Investors
Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, The Venture Collective, Human Ventures, LongeVC
#9
Funding Raised · San Diego, California · founded 2014 · 4 employees$19.4Mraised▾
Funding Raised · San Diego, California · founded 2014 · 4 employees
Data-driven drug discovery using multi-omics, AI, and disease models. The company is transforming drug discovery by applying high-throughput multi-omics data, AI/machine learning, network analyses, and disease models to identify novel targets and mechanisms. Their LEADS® platform combines high-throughput screening, multi-omics data, AI, and network analyses to accelerate the discovery of first-in-class therapeutics. They focus on areas with high clinical unmet need, including neurology, oncology, and genetic diseases. By leveraging advances in metabolomics technologies and computational data analysis, they study diseases and compounds at an unprecedented level of biomolecular detail. This approach enables superior predictivity and facilitates the development of innovative medicines. The company collaborates with leading groups to explore therapeutic areas, offering a data-driven approach to advance drug discovery efforts.
Fliar Intelligence Index™ 13how this company ranks against its industry peers
Funding
top 28%AI
top 45%Global
bottom 29%Tech
bottom 26%Market
bottom 16%Funding: Raised $19.4M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) · Last round Grant (prize money) (Mar 2026)
AI: Product described with: machine learning
Global: Single-market focus (United States)
Audience (LinkedIn): 524 LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Ono Pharmaceutical Co., Ltd.) announced in 12 mo
Funding rounds
- Mar 2026Grant (prize money)—
- Dec 2025Grant (prize money)—
- May 2025Grant (prize money)$318.3K
- Sep 2024Grant (prize money)$2.2M
Investors
NIH, NIDCR, NINDS, HHS, NIGMS, National Cancer Institute
#10
Seed · San Francisco, California · founded 2023 · 11 employees$16Mraised▾
Seed · San Francisco, California · founded 2023 · 11 employees
Developer of next generation of induced-proximity medicines. The company uses the OmniTAC drug discovery engine which yields molecules that co-opt existing cellular machinery to overcome exigent therapeutic challenges for oncology indications.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 31%Talent
bottom 49%Global
bottom 48%Tech
bottom 42%Market
bottom 24%Funding: Raised $16.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (May 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Investors from 1 country beyond United States
Funding rounds
- May 2026Seed—
- Jan 2025Seed$16M
Founders & team
Investors
Y Combinator, age1, Modi Ventures, Wilson Sonsini Goodrich & Rosati, FreeMind Group, Daewoong Pharmaceutical
#11
Eikon 🦄Public · Millbrae, California · founded 2019 · 331 employees$668Mraised▾
Eikon 🦄
Public · Millbrae, California · founded 2019 · 331 employees
Protein tracking and measuring tool for drug discovery. The company has developed a therapeutic discovery platform that assists researchers to analyze targeting protein dynamics for the drug discovery process. It uses technology platform that combines live-cell super-resolution microscopy, comuting and engineering.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 14%News
top 28%Moat
top 28%Market
top 38%Growth
top 40%Tech
top 43%Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Feb 2025)
News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Moat: Editorial + unicorn rating 9/10 · IP moat: 9 patents · Unicorn
Audience (LinkedIn): 32k LinkedIn followers — 3.5% of this cohort's audience · 139 engagements/post (4.6× cohort median)
Funding rounds
- Feb 2025Series D$350.7M
- Jun 2023Series C$140.8M
- Jan 2022Series B$517.8M
- May 2021Series A$148M
Founders & team
Investors
The Column Group, Foresite Capital, Innovation Endeavors, Lux Capital, T. Rowe Price, CPP Investments
Tech stack
Amazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementDocusign
#12
Series A · San Diego, California · founded 2003 · 8 employees$24Mraised▾
Series A · San Diego, California · founded 2003 · 8 employees
Software-based financial management platform for clinical industries. It automates and manages clinical accruals, financial insights, cash planning, accruals, financial planning, analytics, audits, scenario cash planning, and more. It also offers solutions for vendor management, document management, and more.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 27%News
top 29%Talent
top 38%Tech
top 45%Moat
top 48%Innovation
bottom 46%Funding: Raised $24.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Mar 2026)
News: 3 BI events in 12 mo (of 5 tracked, 3 types) · +200% YoY · Top themes: Funding
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Mar 2026Series A$24M
Founders & team
Investors
Insight Partners, Felicis Ventures, 645 Ventures, SNR, Prebysfdn, Bramalea Partners
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesApple Icloud MailCloudflareCloudflare Bot Management
Funding & investor landscape
$15.6Btotal disclosed funding
308companies funded
903disclosed rounds
9rounds last 90 days
Most active investors
Notable founders
Fred Manby
Co-Founder & CTO · Iambic Therapeutics
Thomas Miller
Co-Founder & CEO · Iambic Therapeutics
Frederik Smits
Co-founder & Managing Director · BrightInsight
Kal Patel D
Co-Founder & CEO · BrightInsight
Howard Chang
Co-Founder · Cartography Biosciences
Ansuman Satpathy
Co-Founder · Cartography Biosciences
Weian Zhao
Co-Founder & CEO · Aureka Biotechnologies
Alon Wellner
VP Biology and co-founder · Aureka Biotechnologies
Joshua Meier
Co-Founder · Chai Discovery
Jack Dent
Co-Founder · Chai Discovery
Hrituraj Singh
Co-Founder & CTO · Triomics
Sarim Khan
Co-Founder & CEO · Triomics
Prism market signals · United States · country-scoped Prism corpus, 2,593,976 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Biotechnology in California is moving
A read on the academic research around Biotechnology in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 465 papers.
UC Davis, Berkeley, and Irvine lead California's optimistically-toned biotechnology research, dominated by CRISPR and genetic engineering, with recent output doubling earlier work.
465 papers · stance +0.52 · 47% breakthrough · 15% concern
top institutions
- University of California, Davis74
- University of California, Berkeley57
- University of California, Irvine51
- University of California, San Francisco49
- University of California, Los Angeles43
leading researchers
Suhas Sureshchandra · A. R. Kurhe · R. R. Raut · S. S. Mirza · G. D. Suryawanshi · Blake A. Simmons
prism intelligence · tone & topics
90% positive · 4% critical tone
Medical ResearchHealthPharmaceuticalsBiologyAgricultureGenetics
▲
Breakthroughs187 · 40%
▼ 43%→39% share
▼0.9× share momentum0 median citations64% since 2021mostly empirical
Genomics and genome research newly emerged with 12 combined papers, while Gene studies tripled (6→18), signaling intensifying genetic-characterization focus.
rising sub-themes (early→recent)
- Gene6→18
- Transcription (linguistics)2→9
- Gene expression3→9
- DNA methylation4→8
- Mutant2→6
Newly emergingGenome 0→6 · Genomics 0→6 · Gene knockdown 0→6
Landmark RNA-programmed genome editing in human cells · 2,139 cites
◆
Advancements154 · 33%
▼ 37%→32% share
▼0.9× share momentum0 median citations64% since 2021mostly empirical
Vermicompost and Eisenia fetida research newly emerged (6–7 papers each), marking an unexpected composting-biotechnology niche rising in California.
rising sub-themes (early→recent)
- Gene1→6
- DNA damage1→5
- Transcriptome1→4
- Population1→4
- Antibody1→3
Newly emergingCompost 0→7 · Eisenia fetida 0→6 · Vermicompost 0→6
Landmark Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated · 2,029 cites
▼
Concerns60 · 13%
▼ 13%→12% share
▼0.9× share momentum0 median citations63% since 2021mostly empirical
Cancer and public health topics newly emerged (3 papers each) while Population concerns doubled (2→4), signaling growing biosafety scrutiny.
rising sub-themes (early→recent)
- Population2→4
Newly emergingCancer 0→3 · Cancer cell 0→3 · Public health 0→3
Landmark Beneficial Biofuels—The Food, Energy, and Environment Trilemma · 1,582 cites
Common questions
How many Life Sciences Tech companies are there in California, United States?
Radar tracks 632 indexable Life Sciences Tech companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences Tech companies in California, United States?
The Life Sciences Tech companies in California, United States on this list have raised a combined $15.6B in disclosed equity funding across 308 funded companies.
Which is the highest-funded Life Sciences Tech company in California, United States?
Xaira is the highest-funded Life Sciences Tech company in California, United States, with $1B in disclosed equity funding.
How many Life Sciences Tech companies in California, United States are funded?
308 of the 632 Life Sciences Tech companies in California, United States on this list have disclosed at least one equity funding round.
How many Life Sciences Tech unicorns are there in California, United States?
9 Life Sciences Tech companies in California, United States on this list are valued at $1B or more.
Who are the top investors in California, United States Life Sciences Tech companies?
The most active investors in California, United States Life Sciences Tech companies on this list include HHS, Y Combinator, Lux Capital, DCVC, National Science Foundation.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.